MECHELEN, BELGIUM--(Marketwired - May 13, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG)
announced today that the Company will present three posters on selective
JAK1 inhibitor GLPG0634 at the EULAR Annual European Congress of
Rheumatology, which will take place from 12-15 June 2013 in Madrid, Spain.
The abstracts are now available online at www.eular.org. Information
going beyond that contained in the abstracts is under embargo until
00:01h of the opening day of the EULAR Congress, Wednesday 12 June.
About candidate drug GLPG0634
GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitor
with selectivity for JAK1 developed by Galapagos. JAKs are critical
components of signalling mechanisms utilized by a number of cytokines
and growth factors, including those that are elevated in rheumatoid
arthritis patients. JAK inhibitors have shown long-term efficacy in
rheumatoid arthritis studies with an early onset of action. GLPG0634
differentiates from other JAK inhibitors in development by specifically
targeting JAK1, a strategy which could result in a better efficacy and
safety profile. GLPG0634 is a fully proprietary program. Upon
successful completion of the Phase 2b studies in RA, AbbVie will license
the program and will assume sole responsibility for Phase 3 clinical
development and global manufacturing.
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized in
novel modes-of-action, with a large pipeline of four clinical, seven
pre-clinical, and 30 discovery small-molecule and antibody programs
in cystic fibrosis, inflammation, antibiotics, metabolic disease, and
other indications. GLPG0634 is an orally-available, selective inhibitor
of JAK1 for the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, about to enter Phase 2b studies. AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will
be responsible for further development and commercialization after
Phase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2
in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974
is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. The Galapagos Group, including fee-for-service companies BioFocus,
Argenta and Fidelta, has 800 employees and operates facilities in
five countries, with global headquarters in Mechelen, Belgium. Further
information at: www.glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could," "stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events, conditions
or circumstances on which any such statement is based, unless required by
law or regulation.
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE